Abstract
The aim of the study was to establish the association of C-reactive protein and fecalcalprotectin with the severity of nonspecific ulcerative colitis and Crohn's disease.Material and methods of the research. 34 patients with ulcerative colitis and 18 peoplewith Crohn's disease were examined. The diagnosis was verified according to clinical,laboratory, immunological and instrumental methods.Research results. It has been proved that the level of calprotectin and C-reactiveprotein in nonspecific ulcerative colitis depended on the disease severity – the highestconcentrations of biomarkers were observed in patients with high severity – 880.0±98.0μg/g calprotectin and 35.6±8,2 mg/l C-reactive protein, p<0.05. The concentration ofcalprotectin correlated with the prevalence of lesions (highest – in total lesions, lowest– in ileitis, p<0.05). Changes of C-reactive protein due to endoscopic features was setas r=0.41, r=0.58 and r=0.72 according to the severity (p<0.05). In Crohn's disease theregression increased due to the endoscopic signs – calprotectin from r=0.45 to r=0.62(p<0.05) and C-reactive protein from r=0.51 to r=0.71 (p<0.05).Conclusions. Thus, the content of fecal calprotectin and C-reactive protein level innonspecific ulcerative colitis and Crohn's disease correlated with the severity of thedisease and prevalences of intestinal lesions. In addition, there is a direct relationshipbetween calprotectin content and endoscopic lesions in inflammatory bowel diseases(p<0.05).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.